Merck (XSWX:MRK) Other Long Term Assets: CHF15,669 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MRK Merck & Co Inc XSWX:MRK
70 GF Score
Price CHF122.12
GF Value CHF95.99
! 7 Warning Signs
View Full Analysis

What is Merck Other Long Term Assets?

Merck XSWX:MRK +1.09% 70 Other Long Term Assets is CHF15,669 Mil as of Jun. 2026. GuruFocus rates XSWX:MRK with a GF Score™ of 70/100 and a GF Value™ of CHF95.99. The stock has 7 warning signs investors should review.

Merck's other long-term assets for the quarter that ended in Jun. 2026 was CHF15,669 Mil.

Merck's quarterly other long-term assets increased from Dec. 2025 (CHF14,996 Mil) to Mar. 2026 (CHF15,593 Mil) and increased from Mar. 2026 (CHF15,593 Mil) to Jun. 2026 (CHF15,669 Mil).

Merck's annual other long-term assets increased from Dec. 2023 (CHF10,374 Mil) to Dec. 2024 (CHF14,305 Mil) and increased from Dec. 2024 (CHF14,305 Mil) to Dec. 2025 (CHF14,996 Mil).

Merck Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Merck's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Other Long Term Assets Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,667.02 8,876.29 10,374.14 14,304.83 14,996.07

Merck Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,364.37 14,594.90 14,996.07 15,593.26 15,669.48
XSWX:MRK
70GF Score
Merck & Co Inc XSWX:MRK
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of CHF15,669 Mil mean?
Merck (XSWX:MRK) has a Other Long Term Assets of CHF15,669 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Merck and its competitors.
Is Merck's Other Long Term Assets too high?
Merck's current Other Long Term Assets is CHF15,669 Mil. Overall, Merck has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Merck's Other Long Term Assets compare to AMGN and ABBV?
Merck's Other Long Term Assets of CHF15,669 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Merck and its competitors. Merck's current Other Long Term Assets is CHF15,669 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Merck (XSWX:MRK) has a current Other Long Term Assets of CHF15,669 Mil. The stock's GF Value™ is CHF95.99, compared to a current price of CHF122.12 — trading 27.2% above its estimated fair value. The current Other Long Term Assets is CHF15,669 Mil. Merck's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Merck (XSWX:MRK), the current Other Long Term Assets is CHF15,669 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (XSWX:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of CHF122.12 is trading 27.2% above its estimated GF Value™ of CHF95.99.

Key valuation signals for XSWX:MRK:

  • Other Long Term Assets: CHF15,669 Mil
  • GF Value™: CHF95.99 vs. price of CHF122.12 (27.2% above fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the XSWX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
70GF Score

Get the complete analysis for XSWX:MRK

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF122.12
Price
CHF95.99
GF Value